Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
601
datasets available to search
ShareScore release 0.9.0
Dataset results
601 results for “breast cancer resistance”
Clonal heterogeneity of endocrine therapy resistance in breast cancer
<p>We barcoded endocrine therapy sensitive cell lines (MCF7 and T47D) and rendered them resistant to commonly applied first line endocrine therapeutics (Tamoxifen and estrogen deprivation). Next, we isolated single cell clones of endocrine therapy resistant populations and subjected clonal cell lines to RNA-Seq and Phosphoproteomics profiling.</p>
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations
<p>This study aims to investigate the accumulation of genomic instability and chromosome segregation errors after the acquisition of resistance to CDK4/6i in ER+ breast cancer and to test the efficacy of mitotic kinase inhibitors as a potential treatment for CDK4/6i-resistant breast cancer patients.</p> <p><strong>This repository contains whole-exome and shallow whole-genome sequencing from luminal breast cancer cell lines (T47D, LY2, MDA-MB-361, CAMA1, MCF7, KPL1, ZR751, HCC1428) both at the untreated or Parental state and post resistance to Palbociclib.</strong></p> <p>Palbociclib resistance was developed by continuous dose-escalation of palbociclib up to 0.5-1 μM until cell growth was observed in the presence of the drug (6-8 months for cell lines). During this time, parental cell lines and organoids were cultured in regular media to match the time spent in culture. Once resistance was established, Palbo-R cell lines were cultured in a regular growth medium without palbociclib. Cells were cultured without palbociclib for at least two weeks before evaluating resistance.</p>
Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Addition of the FGFR TKI erdafitinib to palbociclib/fulvestrant induced complete responses of FGFR1-amplified/ER+ patient-derived-xenografts. Next generation sequencing of circulating tumor DNA (ctDNA) in 34 patients after progression on CDK4/6 inhibitors identified FGFR1/2 amplification or activating mutations in 14/34 (41%) post-progression specimens. Finally, ctDNA from patients enrolled in MONALEESA-2, the registration trial of ribociclib, showed that patients with FGFR1 amplification exhibited a shorter progression-free survival compared to patients with wild type FGFR1. Thus, we propose breast cancers with FGFR pathway alterations should be considered for trials using combinations of ER, CDK4/6 and FGFR antagonists.
High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients
<p>High CD8 + / FOXP3+ Ratio is Significantly Associated with Primary Endocrine Therapy Resistance Occurrence in Locally Advanced Luminal B Her-2 Negative Breast Cancer Patients</p>
Supplemental Data for "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"
<p>Supplemental data files for Bahnassy et al, "Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer"</p>
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
ClinicalTrials.gov study NCT02860000. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
ClinicalTrials.gov study NCT02129556. IPD Sharing: Not stated. Countries: 5. Publications: 5.
Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Open the record for dataset details and reuse information.
NanoString dataset for study: Dynamic changes in the NK-, Neutrophil-, and B-cell immunophenotypes relevant in high metastatic risk post neoadjuvant chemotherapy–resistant early breast cancers
<p>Pre-processed DSP and mRNA abundance datasets used in this study.</p>
Data and Code for "Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancer"; Parsons et al. 2024
<p>Data and code for the manuscript <em>Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancer</em> (Parsons et al. 2024).</p> <p>Data: `parsons_her2_tki_data.tar.gz`</p> <p>Code: `parsons_her2_tki_code.tar.gz`</p> <p>The code may also be obtained from our GitHub repository:<br>https://github.com/getzlab/parsons_her2_tki_manuscript<br><br><br></p>
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
ClinicalTrials.gov study NCT01437566. IPD Sharing: Not stated. Countries: 23. Publications: 1.
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov study NCT00002826. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors
ClinicalTrials.gov study NCT00662103. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer
ClinicalTrials.gov study NCT01088477. IPD Sharing: Not stated. Countries: 1. Publications: 3.
The Resistance and Immune Response to Palbociclib in Breast Cancer
ClinicalTrials.gov study NCT03401359. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer
ClinicalTrials.gov study NCT00428896. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Insulin Resistance and Breast Cancer
ClinicalTrials.gov study NCT00304941. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
ClinicalTrials.gov study NCT02530411. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
ClinicalTrials.gov study NCT04549207. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Effect of Resistance Training Variable Manipulation in Postmenopausal Breast Cancer Survivors.
ClinicalTrials.gov study NCT03644329. IPD Sharing: NO. Countries: 1. Publications: 58.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.